Clinical Interventions on Drug Interactions Frequently Required During Treatment
the Cancer Therapy Advisor take:
According to a new study published in the journal Annals of Oncology, researchers from the Netherlands have found that clinical interventions on drug-drug interactions are frequently required among ambulatory patients with cancer starting anticancer treatment.
Drug-drug interactions are a major concern in oncology because patients may take many concomitant medications.
Therefore, researchers sought to investigate the total number of clinical interventions on drug-drug interactions among a sample of ambulatory patients with cancer starting anticancer treatment.
The researchers enrolled 302 patients. Drug interaction software identified 603 drug-drug interactions among these patients, and an expert team of clinical pharmacologists determined that 120 of those among 81 patients were potentially clinically relevant.
Of those, 13% already had a clinical intervention executed by the hemato(oncologist), but the clinical pharmacologists proposed an additional intervention in 14% of patients. The researchers identified the number of over-the-counter medications and the number of comorbidities as determinants.
The findings suggest that structured screening by (hemato)oncologists and clinical pharmacologists/pharmacists for potentially clinically relevant drug-drug interventions should occur prior to and during anticancer treatment.
Clinical interventions on drug-drug interactions are frequently required among ambulatory patients with cancer starting anticancer treatment.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- Clinical Applications of Liquid Biopsies in Cancer
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Investigational Antiandrogen Drug Delays Metastasis in CRPC
- Radical Prostatectomy Compared With Watchful Waiting in Localized Prostate Cancer
- Opinion: Understanding the FDA's Take on Cannabidiol
- High IDO1 Tumor Expression May Predict Poor Overall Survival in Patients With Anal Cancer
- Ambient Benzene Exposure and Risk of Hematologic Malignancies
- Tivozanib Offers Superior Outcomes in Refractory Metastatic Renal Cell Carcinoma
- First-Line Pembrolizumab Shows Promise in Non-Clear Cell RCC